Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-17, Stock:LLY, The news for the past five days is as follows:
2019-06-10: NEWS1: Top Analyst Reports for Oracle, Eli Lilly & Mondelez.NEWS2: Top Analyst Reports for Oracle, Eli Lilly & Mondelez.NEWS3: Top Analyst Reports for Oracle, Eli Lilly & Mondelez.NEWS4: Notable Two Hundred Day Moving Average Cross - LLY.NEWS5: Notable Two Hundred Day Moving Average Cross - LLY.NEWS6: New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria.NEWS7: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca.NEWS8: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca.NEWS9: Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet.NEWS10: Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet.NEWS11: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca.NEWS12: Eli Lilly stock down 2.4% after Trulicity trial misses investors&apos; expectations.NEWS13: Eli Lilly Stock Is Falling and Novo Nordisk Is Rising on Diabetes-Drug Results.NEWS14: Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet.NEWS15: Thor Industries and Eli Lilly Offer a Tale of Two Stocks.NEWS16: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS17: Better Buy: Eli Lilly vs. AbbVie.NEWS18: Better Buy: Eli Lilly vs. AbbVie.
2019-06-11: NEWS1: The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest.NEWS2: Merck (MRK) to Buy Private Biotech Tilos for Up to $773M.NEWS3: Merck (MRK) to Buy Private Biotech Tilos for Up to $773M.NEWS4: Lilly Announces Tradjenta Cardiovascular Outcome Study Data.NEWS5: Lilly Announces Tradjenta Cardiovascular Outcome Study Data.NEWS6: Lilly Announces Tradjenta Cardiovascular Outcome Study Data.NEWS7: Merck (MRK) to Buy Private Biotech Tilos for Up to $773M.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS9: The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering.NEWS10: Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology.NEWS11: Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®.
2019-06-12: NEWS1: Jim Cramer: A Tale of Two Stocks.NEWS2: Galapagos Ends Enrollment in Osteoarthritis Study Before Time.NEWS3: Beware the Risks in These 13 Blue-Chip Stocks.NEWS4: Beware the Risks in These 13 Blue-Chip Stocks.NEWS5: Boost Your Portfolio's Health With These 3 Big Drug Stocks.NEWS6: Boost Your Portfolio's Health With These 3 Big Drug Stocks.NEWS7: 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit.NEWS8: 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit.NEWS9: Boost Your Portfolio's Health With These 3 Big Drug Stocks.
2019-06-13: NEWS1: After Hours Most Active for Jun 13, 2019 :  GE, HAL, CZR, PG, LVS, LLY, HPE, AAPL, FLEX, CMCSA, CINF, ZNGA.NEWS2: After Hours Most Active for Jun 13, 2019 :  GE, HAL, CZR, PG, LVS, LLY, HPE, AAPL, FLEX, CMCSA, CINF, ZNGA.NEWS3: Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s.NEWS4: 3 Top Diabetes Stocks to Watch in June.NEWS5: 3 Top Diabetes Stocks to Watch in June.NEWS6: Thursday Sector Laggards: Healthcare, Utilities.NEWS7: Thursday Sector Laggards: Healthcare, Utilities.NEWS8: NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag.NEWS9: NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag.NEWS10: NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag.NEWS11: Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study.NEWS12: Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study.NEWS13: Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish.NEWS14: Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study.
2019-06-14: NEWS1: U.S. drugmakers file lawsuit against rule requiring drug prices in TV ads.NEWS2: Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod.NEWS3: Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology.NEWS4: Drugmakers sue to stop rule requiring prices in TV ads.

Answer: Rise